Metabolic alterations in patients with Parkinson disease and visual hallucinations

Archives of Neurology

Volumn 64, Issue 7, 2007, Pages 984-988

  Boecker, Henning ^a,c   Ceballos Baumann, Andres O ^a   Volk, Dominik ^a   Conrad, Bastian ^a   Forstl, Hans ^a   Haussermann, Peter ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE INTAKE; HUMAN; MALE; METABOLIC DISORDER; METABOLIC RATE; NEUROPSYCHIATRIC INVENTORY SUBSCALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; UNIVERSITY HOSPITAL; VISUAL CORTEX; VISUAL HALLUCINATION;

AGED; BRAIN; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL LATERALITY; GLUCOSE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; VISUAL CORTEX; VISUAL PATHWAYS;

EID: 34447283494     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.7.984     Document Type: Article

References (36)

1. Diederich NJ, Goetz CG, Raman R, Peppert EF, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998;21(5):289-295.
2. Büttner T, Kuhn W, Muller T, et al. Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J Neural Transm. 1996;103(10):1195-1204.
3. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727-733.
4. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70(6):734-738.
5. Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J. 1989;65(764):358- 361.
6. Klein C, Kompf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson's disease. J Neurol. 1997;244(6):371-377.
7. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50(2):515-517.
8. Perry EK, Kerwin J, Perry RH, Blessed G, Fairbairn AF. Visual hallucinations and the cholinergic system in dementia [letter]. J Neurol Neurosurg Psychiatry. 1990;53(1):88.
9. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12(4):253-256.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
11. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124.
12. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5)(suppl 6):S10-S16.
13. Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med. 1992;33(8):1579-1585.
14. Talairach J, Tournoux P. A Co-Planar Stereotaxic Atlas of a Human Brain. Stuttgart, Germany: Georg Thieme Verlag; 1988.
15. Fénelon G, Mahieux F. Hallucinations and dementia: prevalence, clinical presentation and pathophysiology [in French]. Rev Neurol (Paris). 2004;160(4, pt 2): S31-S43.
16. Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry. 2003;74(4):419-422.
17. Wu JC, Iacono R, Ayman M, et al. Correlation of intellectual impairment in Parkinson's disease with FDG PET scan. Neuroreport. 2000;11(10):2139-2144.
18. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50(3):358-365.
19. Lance JW. Simple formed hallucinations confined to the area of a specific visual field defect. Brain. 1976;99(4):719-734.
20. Ghaem O, Mellet E, Crivello F, et al. Mental navigation along memorized routes activates the hippocampus, precuneus, and insula. Neuroreport. 1997;8(3):739-744.
21. Culham JC, Brandt SA, Cavanagh P, Kanwisher NG, Dale AM, Tootell RB. Cortical fMRI activation produced by attentive tracking of moving targets. J Neurophysiol. 1998;80(5):2657-2670.
22. Mühlau M, Hermsdorfer J, Goldenberg G, et al. Left inferior parietal dominance in gesture imitation: an fMRI study. Neuropsychologia. 2005;43(7):1086-1098.
23. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391-403.
24. Ranganath C, DeGutis J, D'Esposito M. Category-specific modulation of inferior temporal activity during working memory encoding and maintenance. Brain Res Cogn Brain Res. 2004;20(1):37-45.
25. Watson JD, Myers R, Frackowiak RS, et al. Area V5 of the human brain: evidence from a combined study using positron emission tomography and magnetic resonance imaging. Cereb Cortex. 1993;3(2):79-94.
26. Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol. 1999;246(5):365-368.
27. Oishi M, Otsubo H, Kameyama S, et al. Ictal magnetoencephalographic discharges from elementary visual hallucinations of status epilepticus. J Neurol Neurosurg Psychiatry. 2003;74(4):525-527.
28. Fink GR, Pawlik G, Stefan H, Pietrzyk U, Wienhard K, Heiss WD. Temporal lobe epilepsy: evidence for interictal uncoupling of blood flow and glucose metabolism in temporomesial structures. J Neurol Sci. 1996;137(1):28-34.
29. Conca A, Fritzsche H, Peschina W, et al. Preliminary findings of simultaneous 18F-FDG and 99mTc-HMPAO SPECT in patients with depressive disorders at rest: differential correlates with ratings of anxiety. Psychiatry Res. 2000;98(1):43-54.
30. Dunn RT, Willis MW, Benson BE, et al. Preliminary findings of uncoupling of flow and metabolism in unipolar compared with bipolar affective illness and normal controls. Psychiatry Res. 2005;140(2):181-198.
31. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord. 2004;19(7):801-806.
32. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci. 1990;31(11):2473-2475.
33. Manford M, Andermann F. Complex visual hallucinations: clinical and neurobiological insights. Brain. 1998;121(pt 10):1819-1840.
34. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci. 1983;59(2):277-289.
35. Tanaka M, Lindsley E, Lausmann S, Creutzfeldt OD. Afferent connections of the prelunate visual association cortex (areas V4 and DP). Anat Embryol (Berl). 1990;181(1):19-30.
36. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18(5):258-264.